{"id":53902,"date":"2015-03-14T18:21:51","date_gmt":"2015-03-14T22:21:51","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/introduire-un-recours-aupres-du-payeur\/"},"modified":"2025-05-07T15:50:48","modified_gmt":"2025-05-07T19:50:48","slug":"introduire-un-recours-aupres-du-payeur","status":"publish","type":"page","link":"https:\/\/www.erdheim-chester.org\/fr\/introduire-un-recours-aupres-du-payeur\/","title":{"rendered":"Introduire un recours aupr\u00e8s du payeur"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_image=\u00a0\u00bbhttps:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2024\/12\/Untitled-design-96-1.png\u00a0\u00bb background_position=\u00a0\u00bbbottom_center\u00a0\u00bb background_vertical_offset=\u00a0\u00bb20%\u00a0\u00bb custom_padding=\u00a0\u00bb20px||20px||true|false\u00a0\u00bb global_module=\u00a0\u00bb28071&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_dmb_breadcrumbs _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb body_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb link_text_color=\u00a0\u00bb#35A4BB\u00a0\u00bb custom_margin=\u00a0\u00bb||5px||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb||0px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_dmb_breadcrumbs][et_pb_heading title=\u00a0\u00bb@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIiwiZW5hYmxlX2h0bWwiOiJvZmYifX0=@\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _dynamic_attributes=\u00a0\u00bbtitle\u00a0\u00bb _module_preset=\u00a0\u00bbdefault\u00a0\u00bb title_font=\u00a0\u00bb&#8211;et_global_heading_font|300|||||||\u00a0\u00bb title_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb title_font_size=\u00a0\u00bb40px\u00a0\u00bb custom_margin=\u00a0\u00bb||3px|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_heading][et_pb_button button_text=\u00a0\u00bbContactez nous\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_button=\u00a0\u00bbon\u00a0\u00bb button_text_size=\u00a0\u00bb15px\u00a0\u00bb button_text_color=\u00a0\u00bb#C02E43&Prime; button_bg_color=\u00a0\u00bbrgba(10,22,64,0.53)\u00a0\u00bb button_border_width=\u00a0\u00bb0px\u00a0\u00bb button_icon=\u00a0\u00bb&#xe60f;||divi||400&Prime; button_icon_color=\u00a0\u00bb#C02E43&Prime; button_icon_placement=\u00a0\u00bbleft\u00a0\u00bb button_on_hover=\u00a0\u00bboff\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb filter_opacity__hover_enabled=\u00a0\u00bbon|hover\u00a0\u00bb filter_opacity__hover=\u00a0\u00bb70%\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1&Prime; admin_label=\u00a0\u00bbsection\u00a0\u00bb _builder_version=\u00a0\u00bb4.16&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row admin_label=\u00a0\u00bbrang\u00e9e\u00a0\u00bb _builder_version=\u00a0\u00bb4.16&Prime; background_size=\u00a0\u00bbinitial\u00a0\u00bb background_position=\u00a0\u00bbtop_left\u00a0\u00bb background_repeat=\u00a0\u00bbrepeat\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.16&Prime; custom_padding=\u00a0\u00bb|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_padding__hover=\u00a0\u00bb|||\u00a0\u00bb][et_pb_text admin_label=\u00a0\u00bbText\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; background_size=\u00a0\u00bbinitial\u00a0\u00bb background_position=\u00a0\u00bbtop_left\u00a0\u00bb background_repeat=\u00a0\u00bbrepeat\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0&Prime;]<\/p>\n<p>La plupart des traitements ECD sont encore consid\u00e9r\u00e9s comme des traitements non homologu\u00e9s, ce qui signifie qu&rsquo;il faut souvent plusieurs appels pour obtenir l&rsquo;approbation des payeurs pour les traitements ECD aux \u00c9tats-Unis. Afin d&rsquo;all\u00e9ger le fardeau que cela repr\u00e9sente pour le personnel m\u00e9dical, des exemples de lettres de recours et d&rsquo;articles de journaux ont \u00e9t\u00e9 rassembl\u00e9s. Les informations suivantes vous guideront dans la proc\u00e9dure d&rsquo;appel afin d&rsquo;obtenir la prise en charge du traitement de votre patient ECD. Pour les patients vivant en dehors des \u00c9tats-Unis, la proc\u00e9dure peut \u00eatre diff\u00e9rente pour obtenir l&rsquo;approbation d&rsquo;un traitement particulier. Cependant, les m\u00eames informations peuvent \u00eatre utiles pour obtenir l&rsquo;approbation d&rsquo;un traitement particulier.    <\/p>\n<p>Travailler avec les compagnies d&rsquo;assurance au cas par cas demande beaucoup de temps et d&rsquo;efforts. Les m\u00e9dicaments utilis\u00e9s pour traiter les Erdheim-Chester Les m\u00e9dicaments utilis\u00e9s pour traiter la maladie d&rsquo;Alzheimer ne font certainement pas exception \u00e0 la r\u00e8gle. Voici quelques-uns des traitements non homologu\u00e9s pour ECD: Anakinra, dabrafenib, trametinib, cobimetinib, cladribine et m\u00e9thotrexate. La plupart des compagnies d&rsquo;assurance disposent d&rsquo;une liste de m\u00e9dicaments n\u00e9cessitant une autorisation pr\u00e9alable, et ces m\u00e9dicaments figurent g\u00e9n\u00e9ralement sur ces listes. Ces m\u00e9dicaments sont co\u00fbteux et difficiles \u00e0 prendre en charge par un patient seul.    <\/p>\n<p>Le processus d&rsquo;\u00e9valuation typique d&rsquo;un payeur consiste pour une infirmi\u00e8re ou un pharmacien \u00e0 examiner la demande et \u00e0 v\u00e9rifier si le m\u00e9dicament est demand\u00e9 pour une indication approuv\u00e9e par la FDA. Si le m\u00e9dicament ne figure pas sur la liste des m\u00e9dicaments approuv\u00e9s par la FDA, la demande est automatiquement rejet\u00e9e. La demande passe alors en phase d&rsquo;appel, g\u00e9n\u00e9ralement aupr\u00e8s d&rsquo;un directeur m\u00e9dical pour une \u00e9valuation plus approfondie. Il existe une grande variabilit\u00e9 \u00e0 ce stade, mais la demande est g\u00e9n\u00e9ralement rejet\u00e9e. Si le m\u00e9dicament est finalement approuv\u00e9, jusqu&rsquo;\u00e0 quatre recours sont parfois n\u00e9cessaires. Lorsque tous les recours internes sont \u00e9puis\u00e9s, le patient a le droit de demander un examen externe. Ce processus est souvent stressant pour le patient et prend du temps pour les m\u00e9decins et le personnel.      <\/p>\n<p>Pour soutenir ces efforts, une collection d&rsquo;articles et une lettre d&rsquo;appel ont \u00e9t\u00e9 cr\u00e9\u00e9es pour les m\u00e9dicaments souvent prescrits et dont la couverture est refus\u00e9e. Les liens suivants vers des articles sur les m\u00e9dicaments et des lettres d&rsquo;appel ont \u00e9t\u00e9 cr\u00e9\u00e9s pour aider le personnel m\u00e9dical \u00e0 obtenir l&rsquo;approbation du traitement par la compagnie d&rsquo;assurance du patient. D&rsquo;autres m\u00e9decins ont r\u00e9ussi \u00e0 utiliser ces formulaires de demande. Les lettres servent de mod\u00e8le pour faciliter les appels, tandis que les articles appuient la demande avec des faits et des r\u00e9sultats m\u00e9dicaux.   <\/p>\n<p><strong>Important &#8211;<\/strong>Il est conseill\u00e9 aux m\u00e9decins et au personnel d&rsquo;utiliser le code ICD-10 D76.3 \u00ab\u00a0Autres syndromes d&rsquo;histiocytose\u00a0\u00bb et\/ou C96A \u00ab\u00a0Sarcome histiocytaire\u00a0\u00bb pour certaines \u00e9tudes d&rsquo;imagerie (en particulier les TEP Scans) dans les applications pour le traitement et le suivi de ECD.<\/p>\n<p>Si vous avez besoin d&rsquo;une aide suppl\u00e9mentaire dans le cadre de ce processus ou si vous souhaitez faire part de vos commentaires, veuillez contacter le ECDGA.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; sticky_enabled=\u00a0\u00bb0&Prime;]<\/p>\n\n<table id=\"tablepress-5\" class=\"tablepress tablepress-id-5\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Treatment<\/th><th class=\"column-2\">Example Appeal Letter<\/th><th class=\"column-3\">Supporting peer-reviewed article links\u00a0(listed according to involvement)<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Anakinra (Kineret)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2019\/10\/Letter-Requesting-Anakinra.docx\" target=\"_blank\">Letter Requesting Anakinra Treatment<\/a><\/td><td class=\"column-3\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Rationale+and+efficacy+of+interleukin-1+targeting+in+Erdheim%E2%80%93Chester+disease\" target=\"_blank\">Bone<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Erdheim%E2%80%93Chester+disease+with+cardiac+involvement+successfully+treated+with+anakinra\" target=\"_blank\">Cardiac<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Successful+treatment+of+Erdheim%E2%80%93Chester+disease+with+combination+of+interleukin-1-targeting+drugs+and+high-dose+glucocorticoids\" target=\"_blank\">CNS<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Treatment+of+pediatric+Erdheim-Chester+disease+with+interleukin-1%E2%80%93targeting+drugs\" target=\"_blank\">Pediatric<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Favorable+radiological+outcome+of+skeletal+erdheim-chester+disease+involvement+with+anakinra\" target=\"_blank\">Skeletal<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Cladribine (Leustatin, Litak or Movectro)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2019\/10\/Letter-Requesting-Cladribine.docx\" target=\"_blank\">Letter Requesting Cladribine Treatment<\/a><\/td><td class=\"column-3\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=24011030\" target=\"_blank\">Comprehensive Review<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Clinical+considerations+and+key+issues+in+the+management+of+patients+with+Erdheim-Chester+Disease%3A+a+seven+case+series\" target=\"_blank\">Multiple Systems<\/a><br \/>\n<a href=\"http:\/\/bjo.bmj.com\/content\/88\/6\/832.full\" target=\"_blank\">Ocular<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Methotrexate (Trexall or Rheumatrex)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2019\/10\/Letter-Requesting-Methotrexate.docx\" target=\"_blank\">Letter Requesting Methotrexate Treatment<\/a><\/td><td class=\"column-3\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=24362833\" target=\"_blank\">Cardiac<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=A+role+for+methotrexate+in+the+management+of+non-infectious+orbital+inflammatory+disease\" target=\"_blank\">Ocular<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Cobimetinib (Cotellic)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2015\/03\/Letter-Requesting-Coverage-of-Cobimetinib.docx\" target=\"_blank\">Letter Requesting Cobimetinib Treatment<\/a><\/td><td class=\"column-3\"><a href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14284\/abstract;jsessionid=8D21486CF8F795BFE6D019B086E24375.f02t03\" target=\"_blank\">Efficacy of Cobimetinib<\/a><br \/>\n<a href=\"https:\/\/www.nature.com\/articles\/s41586-019-1012-y\" target=\"_blank\">Efficacy of MEK Inhibition<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Trametinib (Mekinist) and\/or Dabrafenib (Tafinlar)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2015\/03\/Letter-Requesting-Coverage-of-Trametinib.docx\" target=\"_blank\">Letter Requesting Trametinib Treatment<\/a><br \/>\n<br \/>\n<a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2015\/03\/Letter-Requesting-Coverage-of-Dabrafenib.docx\" target=\"_blank\">Letter Requesting Dabrafenib Treatment<\/a><\/td><td class=\"column-3\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5291734\/\" target=\"_blank\">Efficacy of Trametinib or Dabrafenib<\/a><br \/>\n<a href=\"http:\/\/www.bloodjournal.org\/content\/129\/7\/879.long?sso-checked=true\" target=\"_blank\">Combined Dabrafenib and Trametinib Treatment<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<p>[\/et_pb_text][et_pb_button button_text=\u00a0\u00bbContactez nous\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb button_url=\u00a0\u00bbhttps:\/\/www.erdheim-chester.org\/fr\/contactez-nous\/\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; sticky_enabled=\u00a0\u00bb0&Prime;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[et_pb_dmb_breadcrumbs _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb body_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb link_text_color=\u00a0\u00bb#35A4BB\u00a0\u00bb custom_margin=\u00a0\u00bb||5px||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb||0px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_dmb_breadcrumbs]La plupart des traitements ECD sont encore consid\u00e9r\u00e9s comme des traitements non homologu\u00e9s, ce qui signifie qu&rsquo;il faut souvent plusieurs appels pour obtenir [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_wds_title":"","_wds_metadesc":"","_wds_focus-keywords":"","_wds_meta-robots-adv":"","_wds_meta-robots-noindex":false,"_wds_meta-robots-nofollow":false,"_wds_meta-robots-index":false,"_wds_meta-robots-follow":false,"_wds_autolinks-exclude":false,"_wds_canonical":"","_wds_redirect":"","_wds_opengraph":[],"_wds_twitter":[],"cybocfi_hide_featured_image":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-53902","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/pages\/53902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/comments?post=53902"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/pages\/53902\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media?parent=53902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}